Sign in

Trial result ·

Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This early-stage trial tested cells made from induced pluripotent stem cells in heart failure. The cells were donor heart muscle cells. They were injected into the heart muscle. The patients had advanced heart failure. Their ejection fraction was reduced. 20 patients were randomized to get the cells or no injection. All had coronary artery bypass grafting. The main outcome was safety. It covered sustained ventricular tachycardia (VT) and tumor formation up to 12 months.

What they found

No sustained VT or tumor formation was seen in either group. Early arrhythmias occurred in the cell group in the first 4 weeks. All 10 patients in that group had accelerated idioventricular rhythm. It emerged 5 to 7 days after transplant. Clinically significant VT occurred in 2 patients. It peaked at 2 to 3 weeks. It resolved after cardioversion. The cell group improved more in 6-min walk distance, myocardial perfusion and relative wall thickening. No significant differences were seen at 12 months. This covered ejection fraction, heart volumes, scar size and quality-of-life scores.

What it means for patients

The authors say cell transplantation gave greater gains than bypass surgery alone. These were in walk distance, blood flow and wall thickening. They say future studies must work out the risk-to-benefit balance because of the arrhythmias.

Why it is not certain yet

20 patients took part. It was an early-stage trial. The main outcome was safety. Efficacy results came from secondary analyses. The cell group had arrhythmias in the first 4 weeks.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial.

PubMed · PMID 42618633

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Heart failure publications